Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal bevacizumab for persistent neovascular activity after panretinal photocoagulation in proliferative diabetic retinopathy
ACTRN12616000737437Phase 3Recruiting
- Sponsor
- Haytham Salti
- Start
- Jun 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bevacizumab in diabetic retinopathy (DR) and proliferative diabetic retinopathy (PDR), sponsored by Haytham Salti. Primary endpoint: Quiescence of neovascular activity. Started Jun 2014; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
diabetic retinopathy (DR)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on ACTRN12616000737437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000737437.